Thanks to its selection for a Ministère de Trade, Industry and Energy project, RudaCure Inc. was able to receive support for raw material pharmaceutique production and formulation research for RCI001. De plus, by being selected for the SME Innovation Growth project, l'entreprise became able to conduct national and international essais cliniques.
RCI001, which has been attracting attention as a substance candidate for traitement de la sécheresse oculaire, demonstrates effets anti-inflammatoires by selectively modulating multifunctional signaling molecules. It is also being developed as an eye drop due to its observed improvement in sécrétion lacrymale function. This new candidat-médicament is targeting essai clinique entry nationalally and internationally l'année prochaine.
